Cell line name |
Hs578T-Dox |
Synonyms |
Hs578T/Doxo |
Accession |
CVCL_IR02 |
Resource Identification Initiative |
To cite this cell line use: Hs578T-Dox (RRID:CVCL_IR02) |
Comments |
Population: Caucasian. Selected for resistance to: ChEBI; CHEBI_28748; Doxorubicin (Adriablastin; Adriamycin). Derived from site: In situ; Breast; UBERON=UBERON_0000310. |
Sequence variations |
- Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:5173; HRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012612; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (from parent cell line).
|
Disease |
Invasive breast carcinoma of no special type (NCIt: C4194) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_0332 (Hs 578T) |
Sex of cell |
Female |
Age at sampling |
74Y |
Category |
Cancer cell line |
Publications | PubMed=7902062 de la Torre M., Hao X.-Y., Larsson R., Nygren P., Tsuruo T., Mannervik B., Bergh J. Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases. Anticancer Res. 13:1425-1430(1993) PubMed=10571255; DOI=10.1016/S0006-2952(99)00262-2 Jonsson O., Behnam-Motlagh P., Persson M., Henriksson R., Grankvist K. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem. Pharmacol. 58:1801-1806(1999) PubMed=15239129; DOI=10.1002/ijc.20300 Cai C.-X., Chen J.-W. Overexpression of caveolin-1 induces alteration of multidrug resistance in Hs578T breast adenocarcinoma cells. Int. J. Cancer 111:522-529(2004) |
Cross-references |
Cell line databases/resources |
cancercelllines; CVCL_IR02
|
Encyclopedic resources |
Wikidata; Q54896337
|
Entry history |
Entry creation | 03-Mar-2017 |
Last entry update | 19-Dec-2024 |
Version number | 14 |
---|